GSK to cut hundreds, not thousands of UK jobs
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is to expand its restructuring programme to deliver a further £500 million in pre-tax savings by 2012. The company plans to cease research into neuroscience areas such as depression, anxiety and pain.